GenFleet’s GFH276 debuts: Pancreatic cancer response rate exceeds Goldman Sachs’ expectations; subsequent dose selection is key
GFH276 achieved an objective response rate of 41% in pancreatic cancer patients treated predominantly in the third-line setting or later, exceeding Goldman Sachs’ previously established threshold. Efficacy and tolerability support further exploration, but higher doses showed no clear efficacy benefit, and skin toxicity and long-term tolerability will influence subsequent dose selection.
Goldman Sachs ·